Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

BUY
$7.51 - $15.0 $600 - $1,200
80 New
80 $0
Q4 2022

Feb 13, 2023

BUY
$13.96 - $20.4 $5,974 - $8,731
428 Added 823.08%
480 $7,000
Q3 2022

Oct 27, 2022

SELL
$17.85 - $26.95 $4,159 - $6,279
-233 Reduced 81.75%
52 $1,000
Q1 2022

May 11, 2022

BUY
$14.38 - $22.79 $4,098 - $6,495
285 New
285 $5,000
Q4 2021

Feb 11, 2022

SELL
$14.98 - $25.5 $1,707 - $2,907
-114 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$19.28 - $27.1 $424 - $596
22 Added 23.91%
114 $3,000
Q2 2021

Aug 05, 2021

BUY
$24.42 - $34.75 $2,246 - $3,197
92 New
92 $3,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $797M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.